Dementia and Medicare at life's end

Area of Science:

• Gerontology
• Health Economics
• Public Health

Background:

• Alzheimer's disease or related dementias (ADRD) are significant public health concerns.
• Understanding the economic impact of ADRD on healthcare systems is crucial for resource allocation.
• Previous studies suggested substantial end-of-life Medicare expenditures associated with ADRD.

Purpose of the Study:

• To evaluate the effect of Alzheimer's disease or related dementias (ADRD) diagnosis on Medicare expenditures.
• To analyze how the timing of an ADRD diagnosis influences end-of-life Medicare spending.

Main Methods:

• Utilized monthly Medicare payment data for 5 years preceding death for decedents between 1996-2000.
• Compared Medicare expenditures (total and service subcategories) for individuals with and without ADRD diagnoses.
• Controlled for demographic factors, comorbidities, and nursing home status using covariate matching.

Main Results:

• ADRD diagnosis was not significantly associated with excess Medicare payments over the last 5 years of life on average.
• No significant 5-year total expenditure differences were found for those diagnosed more than 1 year before death.
• Significant Medicare payment increases were observed primarily around the time of diagnosis, especially for those diagnosed within the last year of life, mainly for acute care services.

Conclusions:

• Alzheimer's disease or related dementias (ADRD) have a less substantial impact on total Medicare expenditures than previously reported.
• The timing of ADRD diagnosis is critical; long-term diagnoses (1+ year before death) do not significantly increase total end-of-life Medicare costs.
• Healthcare cost implications of ADRD are concentrated around the diagnostic period rather than the entire end-of-life trajectory.